Pharmalink AB has entered into a service contract with GP Pharm for the manufacture of Pharmalink’s Busulipo, which is being developed as a conditioning agent for use prior to bone marrow transplantation. The agreement covers the manufacture of Busulipo from clinical to commercial quantities. Financial terms were not disclosed. GP Pharm focuses on injectable oncology products and also offers contract development and manufacturing services.
Johan Häggblad, managing director of Pharmalink, said, “Busulipo is an immediate release liposome formulation that improves the safety and stability of the chemotherapy agent busulfan that is currently the gold standard for use in conditioning prior to HSCT. Busulipo allows the elimination of the toxic solvent DMA and has been designed to have a two-year shelf life and increased stability after reconstitution. GP Pharm has an excellent track record in the manufacturing of complex injectables and specifically with liposomes. We look forward to working with GP Pharm as Busulipo enters the next phase of clinical development.”
Pharmalink is currently preparing the late stage clinical trials needed for registration of Busulipo in key global markets.